Market Overview

Bank Of America Upgrades BioCryst As Financing Overhang Lifts Partially

Bank Of America Upgrades BioCryst As Financing Overhang Lifts Partially

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) completed a $55 million equity raise earlier this week.

While further financing may be needed to make the company launch ready, the recent equity raise has provided “some cushion,” according to Bank of America.

The Analyst

BofA’s Tazeen Ahmad upgraded BioCryst Pharmaceuticals from Neutral to Buy, while lowering the price target from $5 to $4.

The Thesis

Doctor checks conducted after the release of pivotal ApeX-2 study results in hereditary angioedema (HAE) had indicated interest in BioCryst Pharma’s ‘7353, given the convenience of its oral dosing, Ahmad said in the upgrade note.

The analyst continued to estimate unrisk-adjusted peak sales of $601 million in 2027 for ‘7353 in prophylactic HAE. He added that the US price of the treatment is estimated at around $400,000 per patient per year, after assuming a discount to competition.

The New Drug Application (NDA) filing of ‘7353 in prophylactic HAE with the European Union this quarter and Japan submission in the first quarter of 2020 are likely to be key near-term catalysts for the stock, Ahmad said.

He mentioned other near-term catalysts for the stock as the Phase III trial for ‘7353 in acute HAE beginning in 2020 and proof-of-concept data in paroxysmal nocturnal hemoglobinuria (PNH) from ongoing ‘9930 study in the first half of 2020.

Price Action

Shares of BioCryst Pharma were up 13.56% to $1.80 at the time of publishing on Friday.

Latest Ratings for BCRX

Jan 2021RBC CapitalMaintainsSector Perform
Dec 2020HC Wainwright & Co.MaintainsBuy
Nov 2020Evercore ISI GroupInitiates Coverage OnOutperform

View More Analyst Ratings for BCRX
View the Latest Analyst Ratings


Related Articles (BCRX)

View Comments and Join the Discussion!

Posted-In: Bank of America Merrill Lynch Tazeen AhmadAnalyst Color Biotech Upgrades Price Target Analyst Ratings General

Latest Ratings

TSLAJP MorganMaintains125.0
INTCTruist SecuritiesMaintains64.0
FBTruist SecuritiesMaintains320.0
AAPLCowen & Co.Maintains153.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at